Cargando…

Immunoprofiling of T cell responses in melanoma patients undergoing CPI therapy

Detalles Bibliográficos
Autores principales:	Talarico, Lee Ann, Grubaugh, Daniel, Yan, Zheng, Alami, Aula, Bodmer, Jean-Luc, Higgins, Darren E, Hodi, F Stephen, Flechtner, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649294/ http://dx.doi.org/10.1186/2051-1426-3-S2-P326

Ejemplares similares

New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay
por: Kallinteris, Nikoletta L, et al.
Publicado: (2015)

Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies
por: Moudgil, Tarsem, et al.
Publicado: (2014)

Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia
por: Hanna, Glenn J., et al.
Publicado: (2021)

Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia
por: Hanna, Glenn J., et al.
Publicado: (2022)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
por: Galon, J., et al.
Publicado: (2016)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Characterization of anticoagulant heparinoids by immunoprofiling
por: Wijnhoven, Tessa J., et al.
Publicado: (2007)

CPI Hard Disk System
Publicado: (2017)

Scotch 777 6250 CPI
Publicado: (2017)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Type I IFN immunoprofiling in COVID-19 patients
por: Trouillet-Assant, Sophie, et al.
Publicado: (2020)

Immunoprofiles of colorectal cancer from Lynch syndrome
por: Walkowska, Joanna, et al.
Publicado: (2018)

Precision immunoprofiling by image analysis and artificial intelligence
por: Koelzer, Viktor H., et al.
Publicado: (2018)

Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment
por: Busse, Antonia, et al.
Publicado: (2020)

Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes
por: Kim, Moonsik, et al.
Publicado: (2020)

Immunoprofiling of Nonarteritic Anterior Ischemic Optic Neuropathy
por: Mesentier-Louro, Louise A., et al.
Publicado: (2021)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients
por: Sandru, Angela, et al.
Publicado: (2015)

Exome sequencing in primary melanoma identifies novel drivers of melanoma progression
por: Montagnani, Valentina, et al.
Publicado: (2015)

The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17
por: Yoon, Hyuk-Jun, et al.
Publicado: (2022)

Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients
por: Sandru, Angela, et al.
Publicado: (2015)

CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins
por: Riecken, Lars Björn, et al.
Publicado: (2016)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Maspin and MCM2 immunoprofiling in salivary gland carcinomas
por: Ghazy, Shaimaa E, et al.
Publicado: (2011)

Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors
por: Poláková, Ingrid, et al.
Publicado: (2019)

Single-cell peripheral immunoprofiling of Alzheimer’s and Parkinson’s diseases
por: Phongpreecha, Thanaphong, et al.
Publicado: (2020)

Immunoprofiling of Drosophila Hemocytes by Single-cell Mass Cytometry
por: Balog, József Á., et al.
Publicado: (2021)

Measurement of PD-L1 in melanoma: a quantitative antibody comparison
por: Sunshine, Joel C, et al.
Publicado: (2015)

3M No. 700 Black Watch 6250 CPI
Publicado: (2017)

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)
por: Montella, Maurizio, et al.
Publicado: (2014)

Cutaneous Immunoprofiles of Three Spotted Fever Group Rickettsia Cases
por: Jia, Na, et al.
Publicado: (2020)

A novel approach to target metastases of melanoma cells in an organ-selective manner
por: Choudhury, Saurav Roy, et al.
Publicado: (2014)

Malignant melanoma: an audit on delay in diagnosis
por: Lee, CWC, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1silei9irqdi9461piacg5btvt